Novo Nordisk is slashing the cash price of its popular GLP-1 medications — Wegovy and Ozempic — by 30% beginning Monday, making the drugs more affordable for people without insurance coverage.
New Monthly Cost
The Danish drugmaker says the new out-of-pocket price for either medication will be $349 per month, down from $499. The reduced rate will be available at roughly 70,000 locations nationwide, including major pharmacies, Walmart and Costco.
Why the Price Is Dropping
Dave Moore, executive vice president at Novo Nordisk, said the company aims to expand access amid a complex U.S. insurance landscape. He noted that the updated pricing and savings options are intended to provide “immediate impact” for patients who lack insurance or choose to self-pay.
Competitive Market and Broader Strategy
The former cash price for Wegovy matched a full dose of Eli Lilly’s competing drug, Zepbound. Novo Nordisk said the price cut is part of a larger effort to broaden access by working with telehealth providers, major retailers and federal officials to lower costs for people living with obesity and type 2 diabetes.
For more on this story, stay tuned to Que Onda Magazine.